enGene Therapeutics (ENGN) Research & Development (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Research & Development of $22.2 million for Q2 2026, up 9.83% year-over-year from $20.2 million in Q2 2025, and little changed quarter-over-quarter from $22.3 million in Q1 2026.
enGene Therapeutics (ENGN) Research & Development (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Research & Development for 4 consecutive years, with $22.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Research & Development rose 9.83% year-over-year to $22.2 million; the TTM figure through Apr 2026 stood at $98.7 million (up 56.73% YoY), while the FY2025 annual figure was $94.5 million, up 146.59% from the prior year.
- Research & Development was little changed at $22.2 million in Q2 2026 per ENGN's latest filing, from $22.3 million in the prior quarter.
- Across five years, Research & Development topped out at $31.7 million in Q4 2025 and bottomed at $3.2 million in Q2 2023.
- Historically, Research & Development has averaged $13.8 million across 4 years, with a median of $11.4 million in 2024.
- Annual changes were most pronounced in 2025 — Research & Development jumped 254.27% — and 2026, when it gained 9.83%.
- enGene Therapeutics' Research & Development stood at $5.7 million in 2023, then surged by 98.78% to $11.3 million in 2024, then soared by 181.4% to $31.7 million in 2025, then tumbled by 30.03% to $22.2 million in 2026.
- Business Quant data shows ENGN's Research & Development at $22.2 million in Q2 2026, $22.3 million in Q1 2026, and $31.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 22.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 22.20 Mn |
| Jan 31, 2026 | 22.26 Mn |
| Oct 31, 2025 | 31.72 Mn |
| Jul 31, 2025 | 22.58 Mn |
| Apr 30, 2025 | 20.21 Mn |
| Jan 31, 2025 | 19.97 Mn |
| Oct 31, 2024 | 11.27 Mn |
| Jul 31, 2024 | 11.55 Mn |
| Apr 30, 2024 | 9.86 Mn |
| Jan 31, 2024 | 5.64 Mn |
| Oct 31, 2023 | 5.67 Mn |
| Jul 31, 2023 | 3.90 Mn |
| Apr 30, 2023 | 3.22 Mn |
| Jan 31, 2023 | 3.67 Mn |